Open AccessPatient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment
Author(s) -
Ajibade Ashaye,
Caitlin Thomas,
Mehul Dalal,
Vamsi Kota,
Nicolas Krucien,
Maria Sae-Hau,
Elisa S. Weiss,
Scott Campbell,
Kevin Marsh
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0082
Subject(s) - medicine , lymphoblastic leukemia , quality of life (healthcare) , affect (linguistics) , chemotherapy , stroke (engine) , disease , oncology , intensive care medicine , leukemia , mechanical engineering , linguistics , philosophy , nursing , engineering
Aim: We examined the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for benefits and risks of tyrosine kinase inhibitors combined with chemotherapy for first-line treatment. Methods: In a discrete choice experiment, 201 patients chose between hypothetical treatment alternatives with varied levels of remission duration and overall survival (OS), and risks of major cardiovascular (CV) events and myelosuppression. Results: Although OS was the most important attribute to patients with Ph+ ALL, they were willing to tolerate a 2.9% increase in CV risk for 1 additional month of OS. Older patients (>59 years) and patients not in remission were less likely to tolerate increased CV risk. Conclusion: Preferences and risk tolerance varied between patients, highlighting the importance of shared decision making when selecting treatments for Ph+ ALL.